サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1387497

多形性膠芽腫（GBMF）市場レポート：2030年までの動向、予測、競合分析

Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.64円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

多形性膠芽腫（GBMF）市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年11月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

多形性膠芽腫（GBMF）の動向と予測

世界の多形性膠芽腫（GBMF）市場は、2024年から2030年までのCAGRが8.2％で、2030年までに推定12億米ドルに達すると予測されます。この市場の主な促進要因は、研究開発費の上昇、多形性膠芽腫（GBMF）の有病率の拡大、有利な規制環境、さらに脳腫瘍の有病率の拡大、強固な製品パイプラインの存在です。世界の多形性膠芽腫（GBMF）市場の将来は、病院、クリニック、外来手術センター市場におけるビジネスチャンスで有望視されています。

多形性膠芽腫（GBMF）市場の洞察

Lucintelは、放射線療法は効率的であり、脳腫瘍の再発症例に強く支持されていることに加え、放射線技術の進歩や生存率の向上により、予測期間中も最大セグメントであり続けると予測しています。

北米は、ヘルスケア分野の発展に対する政府の支援、希少疾患に関する幅広い認知、質の高い医療機関への便利なアクセス、有利な償還政策により、予測期間中も最大地域であり続けると思われます。

本レポートでは、以下の11の主要な質問に回答している：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の多形性膠芽腫（GBMF）市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の多形性膠芽腫（GBMF）市場動向（2018-2023）と予測（2024-2030）
  • 治療別の世界の多形性膠芽腫（GBMF）市場
    • 手術
    • 放射線療法
    • 化学療法
    • 標的療法
    • 腫瘍治療電場療法
    • 免疫療法
  • 医薬品別の世界の多形性膠芽腫（GBMF）市場
    • テモゾロミド
    • ベバシズマブ
    • ロムスチン
    • カルムスチンウエハース
    • その他
  • 最終用途別の世界の多形性膠芽腫（GBMF）市場
    • 病院
    • クリニック
    • 外来手術センター

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の多形性膠芽腫（GBMF）市場
  • 北米の多形性膠芽腫（GBMF）市場
  • 欧州の多形性膠芽腫（GBMF）市場
  • アジア太平洋の多形性膠芽腫（GBMF）市場
  • その他地域の多形性膠芽腫（GBMF）市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 治療別の世界の多形性膠芽腫（GBMF）市場の成長機会
    • 医薬品別の世界の多形性膠芽腫（GBMF）市場の成長機会
    • 最終用途別の世界の多形性膠芽腫（GBMF）市場の成長機会
    • 地域別の世界の多形性膠芽腫（GBMF）市場の成長機会
  • 世界の多形性膠芽腫（GBMF）市場における新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の多形性膠芽腫（GBMF）市場の能力拡大
    • 世界の多形性膠芽腫（GBMF）市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Merck & Co
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Pharmaceuticals
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics
  • Sumitomo Dainippon Pharma Oncology
目次

Glioblastoma Multiforme Trends and Forecast

The future of the global glioblastoma multiforme market looks promising with opportunities in the hospitals, clinics, and ambulatory surgical centers markets. The global glioblastoma multiforme market is expected to reach an estimated $1.2 billion by 2030 with a CAGR of 8.2% from 2024 to 2030. The major drivers for this market are rising R&D costs, expanding glioblastoma multiforme prevalence, and advantageous regulatory environments, as well as, growing prevalence of brain cancers and having a robust product pipeline.

A more than 150-page report is developed to help in your business decisions.

Glioblastoma Multiforme by Segment

The study includes a forecast for the global glioblastoma multiforme by treatment, drug, end use, and region.

Glioblastoma Multiforme Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Tumor Treating Field Therapy
  • Immunotherapy

Glioblastoma Multiforme Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

  • Temozolomide
  • Bevacizumab
  • Lomustine
  • Carmustine Wafers
  • Others

Glioblastoma Multiforme Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Glioblastoma Multiforme Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Glioblastoma Multiforme Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glioblastoma multiforme companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glioblastoma multiforme companies profiled in this report include-

  • Merck & Co
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Pharmaceuticals
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics
  • Sumitomo Dainippon Pharma Oncology

Glioblastoma Multiforme Market Insights

Lucintel forecasts that radiation therapy will remain the largest segment over the forecast period because it is efficient and strongly endorsed for recurring cases of brain tumors, as well as, advancements in radiation technology and increased survival rates.

North America will remain the largest region over the forecast period due to government backing for healthcare sector advancement, widespread awareness regarding rare disorders, convenient access to high-quality medical institutions, and favorable reimbursement policies in this region.

Features of the Global Glioblastoma Multiforme Market

Market Size Estimates: Glioblastoma multiforme market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glioblastoma multiforme market size by treatment, drug, end use, and region in terms of value ($B).

Regional Analysis: Glioblastoma multiforme market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatment, drug, end use, and regions for the glioblastoma multiforme market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glioblastoma multiforme market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the glioblastoma multiforme market size?

Answer: The global glioblastoma multiforme market is expected to reach an estimated $1.2 billion by 2030.

Q2. What is the growth forecast for glioblastoma multiforme market?

Answer: The global glioblastoma multiforme market is expected to grow with a CAGR of 8.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the glioblastoma multiforme market?

Answer: The major drivers for this market are rising R&D costs, expanding glioblastoma multiforme prevalence, and advantageous regulatory environments, as well as, growing prevalence of brain cancers and having a robust product pipeline.

Q4. What are the major segments for glioblastoma multiforme market?

Answer: The future of the global glioblastoma multiforme market looks promising with opportunities in the hospitals, clinics, and ambulatory surgical centers markets.

Q5. Who are the key glioblastoma multiforme market companies?

Answer: Some of the key glioblastoma multiforme companies are as follows:

  • Merck & Co
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Pharmaceuticals
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics
  • Sumitomo Dainippon Pharma Oncology

Q6. Which glioblastoma multiforme market segment will be the largest in future?

Answer: Lucintel forecasts that radiation therapy will remain the largest segment over the forecast period because it is efficient and strongly endorsed for recurring cases of brain tumors, as well as, advancements in radiation technology and increased survival rates.

Q7. In glioblastoma multiforme market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to government backing for healthcare sector advancement, widespread awareness regarding rare disorders, convenient access to high-quality medical institutions, and favorable reimbursement policies in this region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the glioblastoma multiforme market by treatment (surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field therapy, and immunotherapy), drug (temozolomide, bevacizumab, lomustine, carmustine wafers, and others), end use (hospitals, clinics, and ambulatory surgical centers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Glioblastoma Multiforme Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Glioblastoma Multiforme Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Glioblastoma Multiforme Market by Treatment
    • 3.3.1: Surgery
    • 3.3.2: Radiation Therapy
    • 3.3.3: Chemotherapy
    • 3.3.4: Targeted Therapy
    • 3.3.5: Tumor Treating Field Therapy
    • 3.3.6: Immunotherapy
  • 3.4: Global Glioblastoma Multiforme Market by Drug
    • 3.4.1: Temozolomide
    • 3.4.2: Bevacizumab
    • 3.4.3: Lomustine
    • 3.4.4: Carmustine Wafers
    • 3.4.5: Others
  • 3.5: Global Glioblastoma Multiforme Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Clinics
    • 3.5.3: Ambulatory Surgical Centers

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Glioblastoma Multiforme Market by Region
  • 4.2: North American Glioblastoma Multiforme Market
    • 4.2.2: North American Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers
  • 4.3: European Glioblastoma Multiforme Market
    • 4.3.1: European Glioblastoma Multiforme Market by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy
    • 4.3.2: European Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers
  • 4.4: APAC Glioblastoma Multiforme Market
    • 4.4.1: APAC Glioblastoma Multiforme Market by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy
    • 4.4.2: APAC Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers
  • 4.5: ROW Glioblastoma Multiforme Market
    • 4.5.1: ROW Glioblastoma Multiforme Market by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy
    • 4.5.2: ROW Glioblastoma Multiforme Market by End Use: Hospitals, Clinics, and Ambulatory Surgical Centers

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Glioblastoma Multiforme Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Glioblastoma Multiforme Market by Drug
    • 6.1.3: Growth Opportunities for the Global Glioblastoma Multiforme Market by End Use
    • 6.1.4: Growth Opportunities for the Global Glioblastoma Multiforme Market by Region
  • 6.2: Emerging Trends in the Global Glioblastoma Multiforme Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Glioblastoma Multiforme Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glioblastoma Multiforme Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Merck & Co
  • 7.2: Amgen
  • 7.3: F. Hoffmann-La Roche
  • 7.4: Pfizer
  • 7.5: Teva Pharmaceutical Industries
  • 7.6: Sun Pharmaceutical Industries
  • 7.7: Pharmaceuticals
  • 7.8: Amneal Pharmaceuticals
  • 7.9: Karyopharm Therapeutics
  • 7.10: Sumitomo Dainippon Pharma Oncology